RegulatoryCompany release

Clene submits FDA application for accelerated approval of ALS candidate CNM-Au8

🇺🇸 Clene Inc. (CLNN) · Wed 04 Nov 2026

The US biotech filed its NDA in October 2026 and says a Phase 3 confirmatory trial will start in Q2 2027, while cash runway extends only to mid-Q1 2027.

Clene Inc. has submitted a new drug application to the US Food and Drug Administration seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis (ALS). According to the company, the filing was made in October 2026.

The submission is supported by neurofilament light chain (NfL) biomarker data and clinical data from the HEALEY ALS Platform Trial and related studies, as summarised by Clene in its third-quarter update published on 4 November 2026.

Clene said it plans to begin the Phase 3 RESTORE-ALS confirmatory trial in the second quarter of 2027. As context, accelerated approval in the US allows a medicine for a serious condition to be authorised on the basis of a surrogate or intermediate endpoint, with confirmatory studies required afterwards.

On finances, the company reported cash of $9.9 million. It said this, together with a $4.0 million registered direct offering completed in September, gives it a runway through mid-Q1 2027.

What it means for your team

  • Regulatory teams should watch for the FDA's filing decision and any signals on how it will treat NfL as a biomarker supporting accelerated approval in ALS.
  • The planned Q2 2027 start of RESTORE-ALS indicates the confirmatory trial would begin after the application is under review, which is a point of interest for post-approval commitments.
  • Market-access and partnering teams should note the short cash runway, which may affect the company's ability to fund trial start-up and launch preparations without further financing.

Company's press release (SEC filing): Clene Inc. ↗

Article written by VigiEye from the official source (Clene Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →